Insulet Corporation (PODD) is poised to gain in the coming quarters owing to the strength of its revolutionary offering, the Omnipod 5 Automated Insulin Delivery (“AID”) system. The flourishing diabetes market raises optimism for the company’s operations. A strong solvent balance sheet is highly encouraging.  Meanwhile, elevated costs and the impact of macroeconomic pressures may adversely affect Insulet’s results of operations.In the past year, this Zacks Rank #3 (Hold) stock has decreased 35.6% against th ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at The Raymond James & Associates 45th Annual Institutional Investors Conference in Orlando on Tuesday, March 5, 2024 at 11:35 a.m. (Eastern Time). To listen to the live audio webcast of the presentation, please visit investors.insulet.com/events. A replay of the webcast will also be available fol ...

Insulet Corporation (PODD) recently received CE mark approval under the European Medical Device Regulation for the added compatibility of the Abbott Laboratories’ (ABT) FreeStyle Libre 2 Plus sensor with its Omnipod 5 Automated Insulin Delivery System. It is applicable for individuals aged two years and above with type 1 diabetes.The Omnipod 5 System consists of the tubeless Pod enhanced with SmartAdjust Technology and the Omnipod 5 Controller with its integrated Smartbolus Calculator.Insulet expects Omnipo ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it has received CE mark approval under the European Medical Device Regulation for the added compatibility of the Abbott FreeStyle Libre 2 Plus sensor with Insulet’s Omnipod 5 Automated Insulin Delivery System for individuals aged two years and older with type 1 diabetes. “The addition of the Abbott FreeStyle ...

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Growth Style Score ...

Insulet (PODD) appears well-positioned on solid prospects in the diabetes market. The company is progressing well with respect to product innovation and geographic expansion. The stock carries a Zacks Rank #2 (Buy) currently.Insulet is witnessing continued uptake of Omnipod through the U.S. pharmacy channel. Insulet continues to drive increased awareness for Omnipod through its direct-to-consumer advertising campaign in the United States and across select international markets. Omnipod is specifically desig ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style Score ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the following appointments to the Company’s Board of Directors, effective January 18: Flavia Pease, Corporate Executive Vice President and Chief Financial Officer at Charles River Laboratories Timothy Stonesifer, Chief Financial Officer at Alcon Inc. In addition, the Company announced Shacey Petrovic and ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2023 on February 22, 2024 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Inves ...

Financial Data and Key Metrics Changes - The company reported total Omnipod growth of over 27%, including US growth of 35%, and total company growth of 25% in Q3 [108] - Adjusted gross margin increased to 66% to 67% for 2023, with a gross margin of 67.8% in Q3, up over 1,200 basis points [85][93] - Adjusted operating margin was 12.2% and adjusted EBITDA was 19.1%, both exceeding expectations due to higher-than-anticipated revenue [88] Business Line Data and Key Metrics Changes - Drug Delivery revenue declined by 27%, slightly below guidance due to a lower forecast from partners [85] - Omnipod 5 adoption is driving significant growth, with expectations for US Omnipod revenue growth raised to 37% to 38% [91] Market Data and Key Metrics Changes - International Omnipod growth is expected to be between 9% to 10%, driven by Omnipod DASH adoption and new launches in the UK and Germany [92] - The company anticipates a favorable foreign currency impact of approximately 100 basis points on international growth [92] Company Strategy and Development Direction - The company is focused on expanding its market presence with Omnipod 5, which is positioned as a leading automated insulin delivery system [110] - There is a strong emphasis on innovation and global market opportunities, with plans for further international expansion [2][112] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth catalysts for 2024, including the integration of new technologies and continued strong demand for Omnipod products [63] - The company is optimistic about the potential for significant growth in the Type 2 diabetes market, particularly with the upcoming FDA filing for Omnipod 5 [60][70] Other Important Information - The company ended the quarter with $685 million in cash and $300 million available under its credit facility, providing flexibility for investments [89] - The Omnipod GO pilot is yielding positive insights into primary care engagement, which is crucial for Type 2 patient management [50][81] Q&A Session Summary Question: What are the growth contributions from upcoming developments? - Management highlighted excitement about growth catalysts, including iOS launch and international expansion, but did not provide specific guidance on contributions [5][6] Question: Were new patient starts a record worldwide? - New customer starts were strong but not a record, marking the second-highest quarter ever [11][12] Question: Update on the search for a new CFO? - The search is ongoing, with confidence in interim CFO Lauren Budden's capabilities [13][14] Question: Insights on margins for next year? - While not providing specific guidance, management is committed to expanding margins, with gross margins for 2023 expected to be between 66% to 67% [16][18] Question: Changes in marketing strategy with GLP adoption? - No changes in marketing strategy were reported, with continued success in customer conversions [21][22] Question: Timeline for returning to double-digit growth in international markets? - Management sees no barriers to growth in new markets, particularly with the launch of Omnipod 5 [27][28] Question: Competitive landscape for tubed and patch pumps? - The company remains confident in its competitive position, asserting that Omnipod 5 is superior to competitors' offerings [56][58] Question: Impact of the SECURE trial on commercial opportunities? - The SECURE trial is progressing well, with expectations to file for FDA approval in 2024 [60][70] Question: How is the company engaging with primary care physicians? - The Omnipod GO pilot is aimed at better understanding and engaging primary care practices [81][82]